LENVIMA

Japan's Eisai sets price tag of about $16,000 on liver cancer drug

The drug was approved as the first therapy in over a decade in the United States to treat previously untreated patients with an advanced or intermediate stage of unresectable hepatocellular carcinoma (HCC).